<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965224</url>
  </required_header>
  <id_info>
    <org_study_id>CCRG 09-003</org_study_id>
    <nct_id>NCT00965224</nct_id>
  </id_info>
  <brief_title>Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma</brief_title>
  <official_title>Therapeutic Efficacy of Wilms Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Myeloid Malignancies and Multiple Myeloma: A Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dendritic cell therapy is a promising strategy for adjuvant cancer therapy in the setting of&#xD;
      minimal residual disease (MRD) to fight off cancer relapse and/or progression. The&#xD;
      investigators already performed a phase I safety study in leukemia patients that were in&#xD;
      complete remission demonstrating the absence of side effects and feasibility of the therapy.&#xD;
      Here, the investigators want to extend on this strategy by studying the clinical efficacy of&#xD;
      autologous DC vaccination in patients with acute and chronic myeloid leukemia and myeloma&#xD;
      patients. Effects of DC therapy on the immune reactivity towards leukemia cells as well as&#xD;
      clinical parameters such molecular MRD monitoring, time to relapse (TTR), progression-free&#xD;
      survival (PFS) and overall survival(OS) will be studied in vaccinated and non-vaccinated&#xD;
      (control) patients. Patients will be vaccinated using their own dendritic cells&#xD;
      electroporated with mRNA coding for the full-length Wilms' tumor antigen WT1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of WT1 mRNA-transfected DC vaccination</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Induction/maintenance of molecular remission as evidenced by molecular MRD monitoring of WT1 (AML, CML and MM) and BCR/ABL RNA (CML) copies in peripheral blood</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to relapse (TTR)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>standard therapy + vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dendritic cell vaccination (active specific immunotherapy)</intervention_name>
    <arm_group_label>standard therapy + vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute Myeloid Leukemia (AML): all FAB subtypes except M3. Extent of disease:&#xD;
&#xD;
               -  clinical remission after at least one course of polychemotherapy&#xD;
&#xD;
               -  high risk of relapse due to age (&gt; 60 years) or poor risk cytogenetic/molecular&#xD;
                  markers or hyperleukocytosis at presentation or previous relapse&#xD;
&#xD;
          -  Chronic myeloid leukemia (CML): patients in chronic phase under therapy with&#xD;
             tyrosinase kinase inhibitors who have sub-optimal response or failure and who are not&#xD;
             eligible for hematopoietic stem cell transplantation.&#xD;
&#xD;
          -  Multiple Myeloma (MM): symptomatic with active disease, independent of earlier and/or&#xD;
             concomitant treatment:&#xD;
&#xD;
               -  Presence of serum/urine M protein (&gt; 3 g/dl)&#xD;
&#xD;
               -  Bone marrow plasmacytosis (&gt;10-30%)&#xD;
&#xD;
               -  Anemia, renal failure, hypercalcemia, and/or lytic bone lesions&#xD;
&#xD;
          -  Overexpression of WT1 RNA in peripheral blood and or bone marrow as assessed by&#xD;
             quantitative RT-PCR at the time of presentation.For CML: residual molecular disease as&#xD;
             demonstrated by BCR-ABL RT-PCR&#xD;
&#xD;
          -  Prior treatments: Patients must have received at least one prior antileukemic&#xD;
             chemotherapeutic regimen and must be more than 1 month past the last treatment.&#xD;
&#xD;
          -  Age: ≥ 18 years&#xD;
&#xD;
          -  Performance status: WHO PS grade 0-1 (Appendix B)&#xD;
&#xD;
          -  Objectively assessable parameters of life expectancy: more than 3 months&#xD;
&#xD;
          -  Prior and concomitant associated diseases allowed with the exception of underlying&#xD;
             autoimmune disease and positive serology for HIV/HBV/HCV&#xD;
&#xD;
          -  No concomitant use of immunosuppressive drugs&#xD;
&#xD;
          -  adequate renal and liver function, i.e. creatinin and bilirubin = 1.2 times the upper&#xD;
             limit of normal&#xD;
&#xD;
          -  absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Women of child-bearing potential should use adequate contraception prior to study&#xD;
             entry and for the duration of study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with concurrent additional malignancy (with exception of non-melanoma skin&#xD;
             cancers and carcinoma in situ of the cervix)&#xD;
&#xD;
          -  Subjects who are pregnant&#xD;
&#xD;
          -  Subjects who have sensitivity to drugs that provide local anesthesia&#xD;
&#xD;
          -  Subjects needing corticosteroids 1 mg/kg during vaccination; corticosteroids are&#xD;
             allowed as part of their treatment when taken ≥ 30 days before the start of&#xD;
             vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Antwerp</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Van Driessche A, Van de Velde AL, Nijs G, Braeckman T, Stein B, De Vries JM, Berneman ZN, Van Tendeloo VF. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy. 2009;11(5):653-68. doi: 10.1080/14653240902960411.</citation>
    <PMID>19530029</PMID>
  </reference>
  <reference>
    <citation>Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009 Mar;14(3):240-52. doi: 10.1634/theoncologist.2008-0165. Epub 2009 Mar 16. Review.</citation>
    <PMID>19289488</PMID>
  </reference>
  <reference>
    <citation>Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Antigen-specific cellular immunotherapy of leukemia. Leukemia. 2005 Nov;19(11):1863-71. Review.</citation>
    <PMID>16121214</PMID>
  </reference>
  <reference>
    <citation>Smits EL, Anguille S, Cools N, Berneman ZN, Van Tendeloo VF. Dendritic cell-based cancer gene therapy. Hum Gene Ther. 2009 Oct;20(10):1106-18. doi: 10.1089/hum.2009.145. Review.</citation>
    <PMID>19656053</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>July 11, 2013</last_update_submitted>
  <last_update_submitted_qc>July 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <keyword>AML (acute myeloid leukemia)</keyword>
  <keyword>CML (chronic myeloid leukemia)</keyword>
  <keyword>MM (multiple myeloma)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

